BIOXYNE LIMITED — M&A Activity 2011

Dec 21, 2011

==> picture [218 x 50] intentionally omitted <==

==> picture [36 x 36] intentionally omitted <==

Probiomics Limited

ABN 97 084 464 193

The Australian Securities Exchange Companies Announcements Office SYDNEY

Suite 1 A, Level 2 802 Pacific Highway Gordon NSW 2072

P: +61 2 9844 5422 F: +61 2 9844 5445 W: www.probiomics.com.au

22 December 2011

Dear Sir/Madam

Offer by Probiomics Limited ACN 084 464 193 (Bidder) for securities in Hunter Immunology Limited ACN 106 556 094 (Target) - Notice of Dispatch of Bidder’s Statement

We hereby give notice, on behalf of the Bidder, in accordance with Section 633, Step 8 of the Corporations Act 2001 (Cth) ( Corporations Act ) that a Bidder’s Statement relating to the abovestated takeover offer ( Offer ), together with an acceptance form, have been sent to each shareholder of the Target in accordance with, and in satisfaction of, the requirements of Section 633(1), Step 6 of the Corporations Act.

The Bidder’s Statement includes the terms of the Offer which is dated 13 December, 2011.

Yours sincerely,

==> picture [98 x 44] intentionally omitted <==

ASHOK JAIRATH

Company Secretary

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary Tel: 02 9844 5422

Email ashok.jairath@probiomics.com.au

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC[® ]

PCC[®] has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics’ commercial objective is to earn royalties from licensing PCC[®] to distribution companies selling products in global markets.

1